FI953534A - Menetelmä sellaisten yksölöiden tunnistamiseksi ja hoitamiseksi, joilla on HLA-C-klooni 10/MAGE-1:tä ekspressoivia syöpäsoluja - Google Patents

Menetelmä sellaisten yksölöiden tunnistamiseksi ja hoitamiseksi, joilla on HLA-C-klooni 10/MAGE-1:tä ekspressoivia syöpäsoluja Download PDF

Info

Publication number
FI953534A
FI953534A FI953534A FI953534A FI953534A FI 953534 A FI953534 A FI 953534A FI 953534 A FI953534 A FI 953534A FI 953534 A FI953534 A FI 953534A FI 953534 A FI953534 A FI 953534A
Authority
FI
Finland
Prior art keywords
mage
clone
individuals
identifying
cancer cells
Prior art date
Application number
FI953534A
Other languages
English (en)
Swedish (sv)
Other versions
FI953534A0 (fi
Inventor
Pierre Van Der Bruggen
Thierry Boon-Falleur
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of FI953534A publication Critical patent/FI953534A/fi
Publication of FI953534A0 publication Critical patent/FI953534A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
FI953534A 1993-01-22 1995-07-21 Menetelmä sellaisten yksölöiden tunnistamiseksi ja hoitamiseksi, joilla on HLA-C-klooni 10/MAGE-1:tä ekspressoivia syöpäsoluja FI953534A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US844693A 1993-01-22 1993-01-22
PCT/US1994/000688 WO1994016713A1 (en) 1993-01-22 1994-01-18 Method for identifying and treating individuals bearing cancer cells that express hla-c-clone 10/mage-1

Publications (2)

Publication Number Publication Date
FI953534A true FI953534A (fi) 1995-07-21
FI953534A0 FI953534A0 (fi) 1995-07-21

Family

ID=21731642

Family Applications (1)

Application Number Title Priority Date Filing Date
FI953534A FI953534A0 (fi) 1993-01-22 1995-07-21 Menetelmä sellaisten yksölöiden tunnistamiseksi ja hoitamiseksi, joilla on HLA-C-klooni 10/MAGE-1:tä ekspressoivia syöpäsoluja

Country Status (10)

Country Link
US (1) US5629166A (fi)
EP (1) EP0680330A4 (fi)
JP (1) JPH08506015A (fi)
CN (1) CN1096584A (fi)
AU (1) AU680236B2 (fi)
CA (1) CA2154468A1 (fi)
FI (1) FI953534A0 (fi)
NO (1) NO952797L (fi)
WO (1) WO1994016713A1 (fi)
ZA (1) ZA94407B (fi)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6328971B1 (en) * 1993-01-22 2001-12-11 Ludwig Institute For Cancer Research MAGE-1 derived nona peptides, and compositions thereof
US5550039A (en) * 1995-03-07 1996-08-27 Hoffmann-La Roche Inc. Oligonucleotide primers for HLA class I B locus DNA typing
WO1998015638A2 (en) * 1996-10-07 1998-04-16 Ludwig Institute For Cancer Research Replication-defective adenoviruses for cancer immunotherapy
US5905145A (en) * 1998-03-06 1999-05-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode TAGE molecules, and uses thereof
US6245525B1 (en) * 1998-07-27 2001-06-12 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US7001999B1 (en) * 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
AU1335601A (en) 1999-10-19 2001-04-30 Ludwig Institute For Cancer Research Mage-a12 antigenic peptides and uses thereof
US7311914B2 (en) * 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
AU2003283963A1 (en) 2002-09-27 2004-04-19 Ludwig Institute For Cancer Research Mage-c2 antigenic peptides and uses thereof
US7338670B2 (en) 2005-04-14 2008-03-04 Duke University Use of an agent that restores tissue perfusion and oxygenation
CN110457630B (zh) * 2019-07-30 2022-03-29 北京航空航天大学 一种开源社区异常点赞用户的识别方法及***

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1

Also Published As

Publication number Publication date
US5629166A (en) 1997-05-13
EP0680330A4 (en) 1998-07-29
ZA94407B (en) 1994-08-26
CA2154468A1 (en) 1994-08-04
FI953534A0 (fi) 1995-07-21
AU680236B2 (en) 1997-07-24
EP0680330A1 (en) 1995-11-08
AU6091394A (en) 1994-08-15
JPH08506015A (ja) 1996-07-02
NO952797D0 (no) 1995-07-14
CN1096584A (zh) 1994-12-21
NO952797L (no) 1995-09-20
WO1994016713A1 (en) 1994-08-04

Similar Documents

Publication Publication Date Title
NL1003465A1 (nl) Implanteerbare transponder en verbeterde samenstellingswerkwijze.
DE59606267D1 (de) Mittel zur Haarbehandlung
DK0729951T3 (da) Naphthylforbindelser, mellemprodukter, præparater og fremgangsmåder
DE3882126T2 (de) Künstliches Beatmungsgerät.
DE69623472T2 (de) Derivate von dolastatin, dreen herstellung un verwendung
DE68910477T2 (de) Fluoreszierende kosmetische Präparate.
FI953534A (fi) Menetelmä sellaisten yksölöiden tunnistamiseksi ja hoitamiseksi, joilla on HLA-C-klooni 10/MAGE-1:tä ekspressoivia syöpäsoluja
DE69614806T2 (de) Zentrifugenrotor sowie verschlussschieber dafür
DE59002510D1 (de) Mittel gegen Keratinschädlinge.
DK169987D0 (da) Human tumor-associated antigen, ca-ou1
NO881245L (no) Kosmetisk lysbeskyttelsespreparat samt fremgangsmaate for fremstilling derav.
DE3851139D1 (de) Tonikhaarlotion.
DE69023803D1 (de) Daten-Kompandierungsverfahren und Daten-Kompressor/Dehner.
DE68906245D1 (de) Therapeutisches mittel gegen aids.
DE69614890D1 (de) Hautstreckmaschine
NO975611L (no) Filtrerende kosmetiske preparater inneholdende dibenzoylmetan, <beta>,<beta>'-difenylakrylat og benzotriazolsilikon
ITBZ950045A0 (it) Gioiello e procedimento per la realizzazione dello stesso.
FR2697750B1 (fr) Préparations cosmétiques revitalisant la peau.
DE59607418D1 (de) Haarbehandlungsmittel
IT1227186B (it) Mezzi di impollinazione artificiale e relativo metodo.
DE59600016D1 (de) Mittel zur Haarbehandlung
DE29512229U1 (de) Sicherungs- und Abseilgerät
KR960036114U (ko) 눈썹화장테
DE29509634U1 (de) Kamm
KR950024315U (ko) 눈썹 화장구